Pharma News

Indian Ranbaxy buys Biovel to strengthen in vaccines and follow-on biologics

Home/Pharma News | Posted 12/02/2010

Ranbaxy Laboratories in India (now part of Daiichi Sankyo) has strengthened its vaccine and biologicals manufacturing capabilities by acquiring India-based Biovel Lifesciences.

Pharmalot: Are pay-for-delay deals good or bad?

Home/Pharma News | Posted 11/02/2010

On 13 January 2010, the Federal Trade Commissioner (FTC) Jon Leibowitz held a press conference to deride the ongoing practice in which brand-name drugmakers offer cash or some other inducement to their generic rivals, which, in turn, agree to delay the marketing of lower-cost copycat medicines.

PhRMA threatens to withdraw US healthcare reform support

Home/Pharma News | Posted 10/02/2010

As reported by PharmaTimes on 18 January 2010, US research-based drugmakers have threatened to withdraw their support for US President Barack Obama’s healthcare reforms unless biological drugs receive 12 years’ guaranteed protection from generic competition.

Innovative biologicals development must be preserved

Home/Pharma News | Posted 26/01/2010

As reported by Gene Quinn on IPWatchdog.com, for many months we have been hearing about the US government attempts to “reform” health care in the United States, and in the first weekend of December 2009 the US Senate was actually working, as the contentious debate continues. Even a relatively rare Presidential visit to Capitol Hill was scheduled for the afternoon of 6 December 2009, presumably so President Obama can rally the troops for whatever lies ahead. While patent policy has not taken centre stage in these debates, it is hard to ignore the under current that rages through the debates. Health care costs too much, so costs need to be contained. Of course, market initiatives like a national heath insurance market, which would lower premiums for everyone overnight, are not being considered.

Pfizer plans to launch biosimilars of Top 10–15 biologicals

Home/Pharma News | Posted 22/01/2010

Pfizer, which became the biggest drugmaker selling widely prescribed pills such as the Lipitor heart medicine, is preparing to enter the business of making cheaper copies of pricey, injectable drugs from biotechnology.

Establishing an API manufacturing base in China

Home/Pharma News | Posted 21/01/2010

According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.

China API sourcing: the way forward

Home/Pharma News | Posted 21/01/2010

According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.

Can China retain its API sourcing appeal?

Home/Pharma News | Posted 21/01/2010

China has a burgeoning active pharmaceutical ingredient (API) manufacturing base, albeit one focused largely on achieving quick profits in the domestic sector. According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.

China's appeal of the Chinese API sourcing market

Home/Pharma News | Posted 21/01/2010

According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.

Sourcing APIs from China

Home/Pharma News | Posted 21/01/2010

According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.